Ian is an independent consultant with expertise in regulatory and scientific aspects of nicotine and tobacco products. His consulting work encompasses clinical and behavioural studies of tobacco and nicotine products for regulatory submissions in the US and Europe, and he has a wealth of experience of both consumer goods and medicinal licensing submissions. His 17 years working in the Tobacco Harm Reduction arena has included roles as Senior Director of Clinical and Regulatory Affairs EMEA with JUUL Labs, Director of Tobacco Research with Celerion, and Principal Scientist and Head of Clinical Research at British American Tobacco. As well as his consulting, Ian is a Scientific Advisory Board Member with Qnovia, a medtech startup seeking authorisation for a novel NRT in the UK and the US, and is also an Independent Non-Exec Director with Advanced Inhalation Rituals (AIR), a global shisha manufacturer.

Christopher Russell, Ph.D. is a behavioural scientist and Director of Russell Burnett Research and Consultancy Ltd (RBRC), Glasgow, United Kingdom. Dr Russell leads the design, conduct, and reporting of perception and behavioural research studies of reduced risk tobacco and nicotine products, including electronic nicotine delivery systems (ENDS, vaping products), heated tobacco products, and nicotine pouches. Studies are designed to yield a range of cross sectional and longitudinal evidence on: (i) the likelihood that tobacco users and non users will initiate use of a new product; (ii) how adult consumers actually use a new product in everyday life; (iii) how cigarette smoking behaviour changes over time concurrent with new product use (e.g., switching, reduction); and (iv) behavioural intentions, risk perceptions, and subjective effects of a new product. These sources of evidence can inform regulatory evaluations of the potential impact of marketing a new tobacco/nicotine product on future tobacco/nicotine use behaviour and population health.